Literature DB >> 11059786

Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia.

A Maity1, N Pore, J Lee, D Solomon, D M O'Rourke.   

Abstract

Glioblastomas are highly vascular malignant brain tumors that often overexpress vascular endothelial growth factor (VEGF). They also frequently overexpress epidermal growth factor receptor (EGFR) and contain regions of hypoxia, both conditions that can induce VEGF. We examined VEGF regulation in U87 MG human glioblastoma cells and in U87/T691 cells, a clonal derivative that contains a truncated erbB2/Neu receptor that interferes with EGFR signaling through the formation of nonfunctional heterodimeric receptor complexes. U87/T691 cells contained approximately one-half as much VEGF mRNA as did U87 MG cells under normoxic conditions (21% oxygen). Pharmacological inhibition of EGFR, Ras, or PI(3) kinase, but not MAP kinase, led to a significant decrease in VEGF mRNA levels in U87 MG cells. VEGF promoter activity in transient transfections was decreased by either pharmacological or genetic inhibition of EGFR, Ras, or phosphatidylinositol 3'-kinase [PI(3) kinase]. However, inhibition of PI(3) kinase or EGFR did not completely abolish induction of VEGF mRNA by hypoxia (0.2% oxygen). Likewise, VEGF mRNA expression was induced 3-fold by hypoxia in EGFR-inhibited U87/T691 cells, comparable with the fold induction seen in parental U87 MG cells, although the absolute level of message under hypoxia was higher in U87 MG cells. In transient transfections, a luciferase reporter construct containing a 1.2-kb fragment of the VEGF promoter, lacking the known hypoxic-responsive element (HRE), showed up-regulation after EGF stimulation to the same degree as the full-length, 1.5-kb VEGF promoter construct retaining the HRE. Furthermore, activity of the HRE-deleted, 1.2-kb promoter luciferase reporter was down-regulated by PI(3) kinase inhibition. Therefore, in glioblastoma cells, transcriptional regulation of the VEGF promoter by EGFR appears to involve Ras/PI(3) kinase and to be distinct from signals induced by hypoxia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059786

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  79 in total

1.  Differential sensitivity of human glioblastoma LN18 (PTEN-positive) and A172 (PTEN-negative) cells to Taxol for apoptosis.

Authors:  Ran Zhang; Naren L Banik; Swapan K Ray
Journal:  Brain Res       Date:  2008-09-04       Impact factor: 3.252

2.  Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas.

Authors:  Y Wu; K Lucia; M Lange; D Kuhlen; G K Stalla; U Renner
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

3.  Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors.

Authors:  S Cascinu; F Graziano; V Catalano; M P Staccioli; S Barni; P Giordani; M C Rossi; A M Baldelli; P Muretto; A Valenti; G Catalano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

Review 5.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

6.  Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.

Authors:  S E Wang; Y Yu; T L Criswell; L M Debusk; P C Lin; R Zent; D H Johnson; X Ren; C L Arteaga
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

Review 7.  Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Authors:  David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

8.  Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy.

Authors:  Jochen Tuettenberg; Rainer Grobholz; Marcel Seiz; Marc A Brockmann; Frank Lohr; Frederik Wenz; Peter Vajkoczy
Journal:  J Cancer Res Clin Oncol       Date:  2009-03-10       Impact factor: 4.553

9.  First line targeted therapies in breast cancer: focus on bevacizumab.

Authors:  Amalia Milano; Gugliemo Nasti; Rosario Vincenzo Iaffaioli; Francesco Caponigro
Journal:  Biologics       Date:  2007-03

10.  Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.

Authors:  George J Cerniglia; Nabendu Pore; Jeff H Tsai; Susan Schultz; Rosemarie Mick; Regine Choe; Xiaoman Xing; Turgut Durduran; Arjun G Yodh; Sydney M Evans; Cameron J Koch; Stephen M Hahn; Harry Quon; Chandra M Sehgal; William M F Lee; Amit Maity
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.